The Heart of the Matter – Is EMPA-REG a Game Changer for Diabetes Management?
The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) study sought to determine the effects of empagliflozin on cardiovascular morbidity and mortality in patients with type 2 diabetes at high risk for CVD. Does the evidence from the EMPA-REG OUTCOME study coupled with the other benefits of SGLT2 inhibitors (reduction in weight and blood pressure, mild adverse effects) make empagliflozin the preferred second-line agent from the treatment of type 2 diabetes?
